Disrupting the PCSK9/LDLR protein–protein interaction by an imidazole-based minimalist peptidomimetic-Reference-Cited by-同舟云学术

Disrupting the PCSK9/LDLR protein–protein interaction by an imidazole-based minimalist peptidomimetic

Published:2016 Issue:41 Volume:14 Page:9736-9740
ISSN:1477-0520
Container-title:Organic & Biomolecular Chemistry
language:en
Short-container-title:Org. Biomol. Chem.

Author:

Stucchi Mattia¹²³⁴⁵,Grazioso Giovanni⁶²³⁴^ORCID,Lammi Carmen⁶²³⁴,Manara Silvia⁶²³⁴,Zanoni Chiara⁶²³⁴,Arnoldi Anna⁶²³⁴,Lesma Giordano¹²³⁴,Silvani Alessandra¹²³⁴^ORCID

Affiliation:

1. Dipartimento di Chimica

2. Università degli Studi di Milano

3. 20133 Milano

4. Italy

5. Dipartimento di Scienze della Vita

6. Dipartimento di Scienze Farmaceutiche

Abstract

We report on a tetraimidazole-based β-strand minimalist peptidomimetic as a novel inhibitor of LDLR–PCSK9 protein–protein interaction, a promising target for hypercholesterolemia.

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Physical and Theoretical Chemistry,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2016/OB/C6OB01642A

Reference51 articles.

1. Protein-Protein Interactions and Cancer: Targeting the Central Dogma

2. Drug-Like ProteinProtein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology

3. Oncogenic protein interfaces: small molecules, big challenges

4. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition

5. The biology and therapeutic targeting of the proprotein convertases

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 inhibitors: a patent review 2018-2023;Expert Opinion on Therapeutic Patents;2024-04-02

2. Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: From phenotypic hit discovery to in vivo tolerability;European Journal of Medicinal Chemistry;2024-02

3. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08

4. Identification of benzothiazoles as novel PCSK9 inhibitors;Bioorganic & Medicinal Chemistry Letters;2024-01

5. Discovery of (2‐(4‐Substituted phenyl)quinolin‐4‐yl)(4‐isopropylpiperazin‐1‐yl)methanone Derivatives as Potent Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors;ChemMedChem;2023-12-13